IRCCS Candiolo
TheCandiolo IRCCS Institute is a center specializing in the treatment of oncological diseases, a national and international reference point for oncology, opened in 1996 thanks to the commitment of the Piedmont Foundation for Cancer Research ETS.
Recognized in 2013 as an Institute for Hospitalization and Treatment with Scientific Character (IRCCS), it is a research hospital where clinical and scientific activities proceed together to provide patients with increasingly effective care, based on state-of-the-art procedures and technologies and constant staff upgrading.
It is part of the Piedmont and Aosta Valley Oncology Network since 2008, adheres to Alliance Against Cancer (ACC) since 2016, and has been a Full Member of theEuropean Organization of Cancer Institutes (OECI) as a Comprehensive Cancer Centre.
Since 2024, it has also been participating in the European Joint Action CCI4EU, which is committed to strengthening regional oncology infrastructure.
It receives more than 35,000 patients each year, with personalized pathways in day hospital or inpatient care.
Our mission: research and care
At Candiolo, research inspires care and care inspires research.
Every day we work with a clear goal: to treat and heal people with cancer in an increasingly effective and personalized way, improving their quality of life and offering them new health perspectives.
Our clinical and scientific activities proceed in synergy to prevent, diagnose, control, and defeat malignancies with increasingly targeted and innovative strategies. At the same time, we are committed to disseminating research advances and training the health and science professionals of today and tomorrow, because shared knowledge is integral to care.
This integration of science and clinical practice is fully realized through participation in national and international clinical trials, which are the bridge between laboratory and patient bedside. As a result of these studies, our patients have access to innovative and promising treatments that are often available years before they become widely available.
Every day at Candiolo, science and treatment meet to build a future in which cancer can be increasingly prevented, controlled and defeated.
A network of collaborations
At IRCCS Candiolo, research and care are also growing thanks to a strong network of scientific and academic collaborations.
We operate under an agreement with theUniversity of Turin and with theItalian Institute for Genomic Medicine (IIGM), two institutions that share with us a commitment to innovation and progress in the fight against cancer.
Collaboration with theUniversity of Turin reinforces our dual vocation for research and education. Through this synergy, researchers, physicians and students work side by side in joint projects, fostering the transfer of scientific knowledge into clinical practice and training the next generation of medical and oncology research professionals.
The partnership with theItalian Institute for Genomic Medicine (IIGM), on the other hand, allows us to integrate cutting-edge genomic research into the patient care pathway. IIGM’s expertise allows us to translate discoveries about the cancer genome into concrete tools to prevent, diagnose, and treat cancers in increasingly precise and personalized ways.
Thanks in part to these synergies, the Candiolo IRCCS is now a center of excellence recognized at the European level, capable of combining education, basic and applied research, technological innovation and patient care in an integrated model of translational and personalized medicine.
Certifications
Our commitment to Quality and Safety has led us to pursue and obtain important certifications of excellence in the health care industry.
In May 2022, the Institute was awarded accreditation by Organization of European Cancer Institutes (OECI https://www.oeci.eu)– the network that groups the most important cancer research and treatment centers in Europe – with the designation of “Comprehensive Cancer Center,” the highest award given by OECI.
This certifies that the Institute meets the highest standards, elaborated at the European level, in the field of oncology patient care and treatment and translational clinical cancer research, focusing on patient-centeredness and involvement and multidisciplinary care.
The Institute’s Transplant Center (included in the Turin Metropolitan Transplant Center Program) has been accredited as a facility of excellence by the European/US JACIE-FACT system and the National Transplant Center since July 2013.
In 2025, the Institute received 3 Pink Stamps, valid for the two-year period 2026-2027, representing the highest recognition of a “woman-friendly” hospital, awarded by the National Observatory on Women’s Health and Gender, in recognition of the attention and efficiency of services dedicated to the prevention, diagnosis and treatment of women’s diseases.
In 2025, the Institute received 1 Blue Stamp from the Onda ETS Foundation for excellence in services in prevention, diagnosis, treatment, and rehabilitation of prostate cancer, with a focus on post-surgical functional complications.
As of November 2022, the Institute has achieved ISO 45001:2018 certification, aimed at implementing and maintaining an effective and efficient occupational health and safety management system, pursuing continuous performance improvement through the identification and assessment of risks.
Since November 2016, the Candiolo Institute has been adopting a Quality Management System focused on process effectiveness and patient satisfaction for which it has obtained Quality Certification according to ISO 9001:2015 by the certifying body Bureau Veritas.
The Bureau Veritas expert panel certified the quality of all business processes pertaining to care, research and staff training, highlighting the committment of senior management, the strong focus on patient care and assistance, and the excellent quality of basic, translational and clinical research.
